TELA Bio (TELA) Q4 2024 earnings summary

Executive summary

• Full-year 2024 revenue grew 19% to $69.3 million, with Q4 revenue up 4% to $17.6 million, marking the first single-digit growth since the pandemic due to salesforce disruptions and external headwinds.

• OviTex and OviTex PRS revenues rose 17% and 21%, with unit sales up 33% and 31% for the year, and OviTex IHR launched successfully.

• Major salesforce realignment in August 2024 led to headcount reductions and unexpected departures, impacting Q4 performance.

• Implemented cost reduction measures, resulting in a sequential decrease in operating expenses from Q3 to Q4 2024.

• Ended 2024 with $52.7 million in cash and cash equivalents.

Financial highlights

• Q4 2024 revenue: $17.6 million (+4% YoY); full-year revenue: $69.3 million (+19% YoY).

• OviTex unit sales grew 28% in Q4 and 33% for the year; PRS unit sales grew 11% in Q4 and 31% for the year.

• Gross margin was 64% in Q4 and 67% for the year, down from 68% and 69% in prior periods due to inventory adjustments.

• Operating loss: $8.4 million in Q4, $34.1 million for the year; net loss: $9.2 million in Q4, $37.8 million for the year, both improved from 2023.

• Net loss per share for 2024: $1.33, improved from $2.04 in 2023.

Outlook and guidance

• 2025 revenue guidance: $85–88 million, representing 23–27% growth over 2024.

• Q1 2025 revenue expected between $17–18 million, up 2–8% year-over-year.

• Operating and net losses projected to decrease in 2025; OpEx expected to remain flat year-over-year.

• Targeting 97 field reps by year-end 2025, with a mix of territory managers and account specialists.